GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Beam Therapeutics Inc.
Beam Therapeutics is a pioneer in base editing, a next-generation CRISPR technology. Its stock price represents a venture bet on a revolutionary approach to treating genetic diseases. The stock price reflects high volatility and dependence on lab news.
Share prices of companies in the market segment - Dna
Beam Therapeutics is a pioneering company in gene editing, specializing in base editing technology. Its business is comprised entirely of this segment. We classify it as part of the DNA sector, and the chart below reflects the dynamics of the entire genetic engineering industry, where value is driven by scientific breakthroughs.
Broad Market Index - GURU.Markets
Beam Therapeutics is a leading company in the field of base editing, a new and more precise method of genetic engineering. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Beam compares to it.
Change in the price of a company, segment, and market as a whole per day
BEAM - Daily change in the company's share price Beam Therapeutics Inc.
Shares of Beam Therapeutics, a pioneer in genome editing, are extremely volatile. Change_co measures the market reaction to news about preclinical and clinical trials. This metric is an essential component in building valuation models for companies at the forefront of science on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
Beam Therapeutics Inc. is a pioneer in DNA base editing. This chart illustrates the extreme volatility of the biotech sector. Comparing it to BEAM, which is a near-pure bet on the success of its unique technology, clearly demonstrates its extreme risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Beam Therapeutics is a pioneer in base editing—a new, more precise method of gene editing. It's one of the most cutting-edge and speculative areas in biotech. The chart below illustrates the extreme volatility typical of this sector, reflecting the enormous expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Beam Therapeutics Inc.
Beam is a pioneer in using base-editing technology to create gene therapies. The company's stock is a bet on a scientific revolution. Its extreme, data-driven volatility is part of the dynamic of the innovation sector.
Annual dynamics of market capitalization of the market segment - Dna
Beam Therapeutics Inc. is a biotechnology company pioneering the development of next-generation gene editing technologies (base editing). Its stock performance is entirely dependent on the results of preclinical and clinical trials. The chart reflects the enormous potential and high risks of this cutting-edge field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Beam Therapeutics, a pioneer in genome base editing, is a bet on the technology of the future. Its stock price is completely unrelated to the economy. Its chart reflects the hopes, risks, and scientific breakthroughs in one of the most cutting-edge fields of medicine. It's a long-term bet on a technology that could change the world.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Beam Therapeutics Inc.
Beam Therapeutics, a pioneer in base editing—a new, more precise method of gene editing. The sharp monthly fluctuations on the chart reflect progress in its preclinical and clinical programs, which is typical for a biotech company at the forefront of science.
Monthly dynamics of market capitalization of the market segment - Dna
Biotechnology, particularly gene editing, is an investment in the future of medicine. The sector's market capitalization, reflected in the chart, is extremely sensitive to news about clinical trials and breakthroughs. This dynamic demonstrates the level of investor faith in the technologies pioneers like Beam Therapeutics are developing, transforming treatment approaches.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Beam Therapeutics, a pioneer in gene editing, is a biotech venture bet. The company's stock price is driven by scientific breakthroughs and clinical trial news, not macroeconomic data, resulting in a complete disconnect from the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Beam Therapeutics Inc.
Beam Therapeutics is a biotech company pioneering base editing, a highly precise gene editing technique. Its weekly stock price is highly volatile, driven by news about preclinical and clinical trials, as well as breakthroughs in gene therapy in general.
Weekly dynamics of market capitalization of the market segment - Dna
Beam Therapeutics, a pioneer in gene editing, exists in its own universe, divorced from the pharmaceutical sector. News of scientific breakthroughs and clinical trials are the only things that drive its stock. The chart clearly demonstrates these sharp, unrelated movements typical of companies at the forefront of science.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Beam Therapeutics is a pioneer in the field of "base editing," one of the most advanced methods of genetic engineering. The company's shares are a clear bet on a future scientific revolution. A chart will show their extreme volatility and complete disconnect from market trends.
Market capitalization of the company, segment and market as a whole
BEAM - Market capitalization of the company Beam Therapeutics Inc.
Beam Therapeutics' market capitalization chart represents investors' bet on the future of genetic engineering, specifically base editing technology. Its price chart is highly volatile and depends on the results of preclinical and clinical trials. The company's valuation is based not on current revenue, but on the enormous potential of its platform for treating genetic diseases.
BEAM - Share of the company's market capitalization Beam Therapeutics Inc. within the market segment - Dna
Beam Therapeutics is a pioneer in base editing—a new, more precise method of genetic engineering. Its market share reflects the potential of this cutting-edge technology for creating treatments for genetic diseases, attracting the attention of investors.
Market capitalization of the market segment - Dna
The chart below shows the overall value of the biotech sector, and Beam Therapeutics is one of its most futuristic players. The company is a pioneer in base editing—an ultra-precise method of genome editing. The potential of this market is enormous, and Beam is at the forefront of gene medicine, reflecting investor interest.
Market capitalization of all companies included in a broad market index - GURU.Markets
Beam Therapeutics is a pioneer in base editing, a new, more precise method of gene therapy. Its market capitalization represents the hope of curing genetic diseases at a fundamental level. The chart below shows the value of this biotech company working at the forefront of science.
Book value capitalization of the company, segment and market as a whole
BEAM - Book value capitalization of the company Beam Therapeutics Inc.
Beam Therapeutics' foundation is its cutting-edge laboratories and intellectual property in base-editing technology—one of the most precise methods of genetic engineering. This chart is a financial timeline of this biotech pioneer, showing how the capital raised is being invested in creating a platform capable of generating a whole new class of drugs.
BEAM - Share of the company's book capitalization Beam Therapeutics Inc. within the market segment - Dna
Beam Therapeutics is a pioneer in gene editing, and its work requires state-of-the-art laboratories. The chart shows the company's share of the biotech sector's actual R&D assets. This is its scientific infrastructure, where technologies capable of changing the future of medicine are being developed.
Market segment balance sheet capitalization - Dna
Beam Therapeutics is a pioneer in genome base editing, and its model is intellectually rather than capital-intensive. The company's value lies in its platform and patents, not its manufacturing facilities. Compared to the broader biotech sector, its "light" balance sheet is typical of companies at the forefront of science, where technology, not production, is paramount.
Book value of all companies included in the broad market index - GURU.Markets
Beam Therapeutics' assets represent intellectual capital capable of rewriting the very code of life. The company's balance sheet reflects the value of its revolutionary gene-editing technology and its pipeline of potential drugs. The chart shows the resources invested in this cutting-edge science aimed at curing genetic diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Beam Therapeutics Inc.
Beam Therapeutics is a company at the forefront of genetic engineering. Its book value is primarily derived from cash flow from research, while its market capitalization is a valuation of its revolutionary genome editing platform. The chart shows how investors assess its chances of creating drugs capable of curing diseases at the DNA level.
Market to book capitalization ratio in a market segment - Dna
Beam Therapeutics is a genome editing company. Its value is almost 100% derived from its intellectual property and future prospects. This chart clearly shows how its market capitalization, based on hopes, is many times greater than the value of its lab equipment. It's a pure venture bet on a scientific breakthrough.
Market to book capitalization ratio for the market as a whole
Beam Therapeutics is a biotech company specializing in gene editing. Its market capitalization is based almost entirely on the potential of its scientific platform, rather than on its physical assets. This chart clearly demonstrates the extreme premium the market pays for breakthrough scientific ideas that have the potential to transform medicine.
Debts of the company, segment and market as a whole
BEAM - Company debts Beam Therapeutics Inc.
Beam Therapeutics is a biotech company working with cutting-edge gene editing technology. Its journey from lab to commercial product requires significant capital for years to come. Its debt strategy is part of its plan to ensure financial stability for preclinical and clinical trials of its innovative therapies.
Market segment debts - Dna
Beam Therapeutics is a biotech company specializing in gene editing. This is a cutting-edge, but extremely expensive, area of research. Debt is rare for such companies; they often rely on equity capital. This chart shows Beam's chosen financial path, which may indicate the maturity of its research and investor confidence.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Beam Therapeutics Inc.
Beam Therapeutics is a biotech pioneering base editing—a new, more precise method of genome editing. This chart shows the company's financial position at the advanced R&D stage. The absence of debt and reliance on equity are typical of companies whose value is based on the potential of their breakthrough scientific platform.
Market segment debt to market segment book capitalization - Dna
Beam Therapeutics is a biotech company working with cutting-edge gene editing technology. This chart illustrates the debt burden in the gene therapy sector, where companies often raise debt to finance long-term research. This allows us to assess how typical Beam's financial model is for innovative companies at the forefront of science.
Debt to book value of all companies in the market
Beam Therapeutics, as a biotech company, rarely uses debt in its early stages. The chart illustrates the overall level of leverage in the economy. It clearly demonstrates the contrast between the financial models of innovative companies funded by venture capital and the mature market, where debt financing is the norm.
P/E of the company, segment and market as a whole
P/E - Beam Therapeutics Inc.
This chart for Beam Therapeutics, a gene-editing company, is a clear bet on a scientific breakthrough. Since the company is in the research stage, any positive profit is highly valued by the market. The indicator's dynamics are not a reaction to revenue, but rather a reflection of news about clinical trials and faith in the revolutionary potential of their technology.
P/E of the market segment - Dna
This chart reflects the average valuation for the entire gene therapy sector, where Beam Therapeutics operates. It's one of the most speculative areas of biotech, and the entire sector is valued based on future breakthroughs. For investors, this benchmark indicates the overall level of faith in gene editing technology, against which Beam's prospects can be assessed.
P/E of the market as a whole
Beam Therapeutics is a biotech company developing cutting-edge gene-editing technology. Its valuation is a bet on a scientific revolution. This chart, reflecting the market's risk appetite, is key for Beam. During periods of euphoria, investors are willing to wait years for results, but during a general downturn, they demand faster and more tangible proof of the platform's success.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Beam Therapeutics Inc.
Beam Therapeutics is at the forefront of genetic engineering, developing DNA base-editing technology to treat diseases. The company's valuation is a bet on a scientific breakthrough. This chart reflects investors' and analysts' belief that the company's technology will pass clinical trials and become commercially successful, generating future profits.
%20P%2FE%20Beam%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Beam-Therapeutics-Inc.&v=1772513720859 "Chart of the company's future (projected) P/E Beam Therapeutics Inc.")
Future (projected) P/E of the market segment - Dna
Beam Therapeutics is a pioneer in base editing, a new approach to gene therapy. Its valuation, relative to other biotech companies, reflects the high expectations surrounding its platform. This premium valuation reflects investors' belief in the revolutionary potential of this technology for treating genetic diseases, despite its early stage of development.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772513720883 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Beam Therapeutics is a biotech company developing cutting-edge gene editing technology (base editing). Its value reflects expectations of future medical breakthroughs. This chart shows investors' overall risk appetite. High market optimism is fueling capital flows into science-intensive, long-term projects like those being pursued by Beam Therapeutics.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513720898 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Beam Therapeutics Inc.
Beam Therapeutics is a biotechnology company specializing in base editing, a more precise form of CRISPR. The financial metrics presented here primarily reflect investments in research. Future results depend on the success of clinical trials and partnerships with major pharmaceutical companies.
Profit of companies in the market segment - Dna
Beam Therapeutics is a biotech company developing cutting-edge genome editing techniques. It's cutting-edge science, but is it profitable? This chart shows the combined financial performance of gene therapy companies. It helps us understand whether the sector is still in the promising but unprofitable research phase or has already begun to recoup its losses.
Overall market profit
Beam Therapeutics is at the forefront of genetic engineering, developing base-editing technology. For a research-stage company, the macroeconomic situation on this chart is important primarily for access to capital. During periods of market optimism, investors are more willing to fund breakthrough but risky biotech projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Beam Therapeutics Inc.
Beam Therapeutics is at the forefront of medical science, developing gene editing technologies. The company doesn't yet have commercial products, so its future profit forecasts are long-term expectations. This chart reflects analysts' belief that the company's scientific platform will ultimately lead to breakthrough and commercially successful drugs.
%20profit%20of%20the%20company%20Beam%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Beam-Therapeutics-Inc.&v=1772513721224 "Graph of future (projected) profit of the company Beam Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Dna
Beam Therapeutics is a biotech pioneering base editing—a highly precise method of altering DNA to treat genetic diseases. This chart shows revenue projections for its segment. Given the early stage of development, it helps us appreciate the enormous potential the industry holds should such breakthrough technologies prove successful.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772513721320 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Beam Therapeutics Inc. is a pioneer in genome editing, a new technology for treating genetic diseases. The overall profit forecast shown here influences investor risk appetite. During periods of economic optimism, venture capital is more likely to flow to biotech companies with long-term, capital-intensive projects, like Beam Therapeutics.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513721413 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Beam Therapeutics Inc.
Beam Therapeutics is a biotech company developing cutting-edge gene editing technology. With minimal or no revenue, its market valuation, reflected in this chart, is purely a bet on the future. Investors are paying for the revolutionary potential of a platform capable of creating cures for previously incurable diseases.
P/S market segment - Dna
Beam Therapeutics is a biotech company at the forefront of genetic engineering using base editing technology. This chart shows the average valuation of biotech companies, often before revenue. It reflects investor confidence in the revolutionary potential of Beam's platform and the gene therapy industry as a whole.
P/S of the market as a whole
Beam Therapeutics Inc. is a biotechnology company developing a new generation of gene therapy based on DNA base editing technology. Its revenue potential lies in the future, following drug approval. This chart shows how well expectations for a medical revolution are reflected in its valuations compared to the overall market average.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Beam Therapeutics Inc.
Beam Therapeutics is a biotech company developing genome editing technology. The company's valuation is based on expected future revenue from potential therapies. This chart illustrates investors' belief that Beam's unique technology will lead to breakthrough drugs and multibillion-dollar sales in the future.
%20P%2FS%20Beam%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Beam-Therapeutics-Inc.&v=1772513721732 "The graph of the company's future (projected) P/S Beam Therapeutics Inc.")
Future (projected) P/S of the market segment - Dna
Beam Therapeutics is a biotech company developing a new class of gene therapy known as "base editing." This technology allows for the targeted correction of DNA errors. The chart shows how the market assesses the commercial potential of this breakthrough technology compared to other companies in the genetic engineering field, reflecting expectations for future treatments.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772513721815 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
This indicator reflects the market's confidence in future breakthroughs and revenue growth. For Beam Therapeutics, a gene editing company, it reflects investor appetite for risky but promising technologies. High market optimism creates a favorable environment for raising the capital needed for lengthy and expensive clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513721853 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Beam Therapeutics Inc.
Beam Therapeutics is a biotech company pioneering base editing, a highly precise method for altering genes. This chart reflects revenue from strategic partnerships and licensing agreements with major pharmaceutical companies. In the future, it will reflect revenue from the commercialization of gene therapy for rare diseases.
Sales of companies in the market segment - Dna
Beam Therapeutics is a biotechnology company pioneering the field of genome editing. This chart shows the overall investment and revenue trends in the gene therapy sector. Beam's technology represents the next generation of gene editing, and its advancement marks a significant milestone in the development of the entire field of personalized medicine.
Overall market sales
Beam Therapeutics Inc. is a biotechnology company specializing in gene editing. Its growth depends on long-term investment in research. The overall economic environment, shown in this chart, influences investors' risk appetite and their willingness to invest in cutting-edge, yet capital-intensive, technologies with a long-term future.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Beam Therapeutics Inc.
Beam Therapeutics is a biotechnology company at the forefront of gene engineering using base-editing technology. Its future revenue depends on the successful development and commercialization of gene therapies. This chart represents analyst consensus on the scientific and commercial potential of Beam's platform and its ability to create breakthrough drugs.
%20sales%20of%20the%20company%20Beam%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Beam-Therapeutics-Inc.&v=1772513722048 "Schedule of future (projected) sales of the company Beam Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Dna
Beam Therapeutics is a biotechnology company pioneering DNA base editing, a more precise method of gene therapy. This forecast reflects expectations for the entire genetic engineering segment. It highlights the growth potential analysts see in this cutting-edge field of medicine, where Beam strives to develop new treatments for genetic diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772513722084 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Beam Therapeutics Inc. is a biotechnology company pioneering the field of genome base editing for the creation of precision genetic drugs. Its market capitalization and success depend on breakthroughs in research and biotech investments. This chart, reflecting the overall market situation, influences investor risk appetite and the funding of long-term scientific projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513722091 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Beam Therapeutics Inc.
Beam Therapeutics is at the forefront of genetic engineering, developing base-editing technology. The chart illustrates the scale of investment in this scientific breakthrough. Negative indicators do not represent losses, but rather investments in clinical trials and a platform that could lead to the creation of revolutionary drugs and high profits in the future.
Market segment marginality - Dna
Beam Therapeutics is at the forefront of gene medicine, developing base-editing technology for disease treatment. Profitability for such a company is a future prospect, dependent on the success of its developments. Its current metric reflects the structure of its R&D investments relative to other DNA biotech companies.
Market marginality as a whole
Beam Therapeutics is a biotech company developing gene-editing technology to treat diseases. This overall profitability curve is of secondary importance to the company. Beam's future profitability depends not on market cycles, but on the success of clinical trials and the ability to create paradigm-shifting drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Beam Therapeutics Inc.
Beam Therapeutics is a biotechnology company pioneering base editing, a highly precise method for altering genomes. The chart illustrates the size of the scientific team advancing this cutting-edge technology. The growth in headcount is directly related to the expansion of research and clinical programs.
Share of the company's employees Beam Therapeutics Inc. within the market segment - Dna
Beam Therapeutics is at the forefront of genetic engineering, using base-editing technology. This chart reflects the percentage of leading scientists in molecular biology and genetics that the company attracts. It demonstrates its status as a key center of excellence, home to the minds shaping the future of medicine at the DNA level.
Number of employees in the market segment - Dna
Beam Therapeutics Inc. is a biotechnology company pioneering the use of DNA base editing technology to create precision genetic drugs. Their approach allows them to correct errors in the genome. This chart shows the growth of employment in the cutting-edge gene therapy sector, reflecting how scientific breakthroughs in treating genetic diseases are shaping a new job market.
Number of employees in the market as a whole
Beam Therapeutics is a biotech company working on genome editing to treat diseases. It's at the cutting edge of science, where value is created not by the number of employees, but by their unique skills. This graph shows quantity, while Beam's growth reflects quality and the direction the labor market is moving, creating jobs that didn't exist yesterday.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Beam Therapeutics Inc. (BEAM)
Beam Therapeutics is a pioneer in genome editing using "prime editing" technology. This chart is a prime example of how to value a biotech breakthrough. Its astronomical market capitalization per employee means the market sees the potential of its platform to create cures for a multitude of genetic diseases, a hope worth billions.
%20of%20the%20company%20Beam%20Therapeutics%20Inc.%20(BEAM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Beam-Therapeutics-Inc.-BEAM&v=1772513722570 "Chart of market capitalization per employee (in thousands of dollars) of the company Beam Therapeutics Inc. (BEAM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Beam Therapeutics is a biotech pioneering base editing, a highly precise form of gene therapy. It's an early-stage R&D company. This chart shows the industry average market capitalization per employee. It helps us understand the enormous market premium their breakthrough technology platform represents per scientist.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772513722617 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Beam Therapeutics is a biotech pioneering base editing for precision genetic drug development. This chart shows the average market value of each employee's contribution. It helps us understand the enormous value the market places on breakthrough scientific platforms.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513722634 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Beam Therapeutics Inc. (BEAM)
Beam Therapeutics is a biotech company working in the cutting-edge field of base editing. This is pure R&D. The company doesn't yet have commercial products, so this graph shows the company's per-employee loss. It reflects how much the company is burning through on each scientist in the race to create a revolutionary drug.
%20Chart%20Beam%20Therapeutics%20Inc.%20(BEAM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Beam-Therapeutics-Inc.-BEAM&v=1772513722653 "Company Profit Per Employee (in thousands of dollars) Chart Beam Therapeutics Inc. (BEAM)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Beam Therapeutics (BEAM) is an R&D biotech company (a pioneer of "base editing" - genome editing). This chart shows the benchmark for "DNA" (Biotech). The average profit per employee in this sector (R&D) is *negative*. This benchmark reflects the "burning" of money in the hope of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772513722733 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Beam Therapeutics is a biotech company working at the cutting edge of science: DNA base editing. This is pure R&D. There is no profit yet. This chart shows operating expenses (loss) per scientist. Investors look at it to estimate the "cost" of breakthrough science and the rate at which capital is spent before results are achieved.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513722745 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Beam Therapeutics Inc. (BEAM)
Beam Therapeutics is a biotech company working in gene editing. This graph illustrates the path from science to commercialization. For a company at the forefront of science, it reflects the potential for monetizing intellectual property, where even a small team of scientists can create technology worth billions.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Beam-Therapeutics-Inc.-BEAM&v=1772513722769 "Sales chart per company employee Beam Therapeutics Inc. (BEAM)")
Sales per employee in the market segment - Dna
Beam Therapeutics is a biotech company working at the cutting edge of base editing. The company is currently in the R&D phase. This chart shows the average revenue per employee in this segment, serving as a productivity benchmark for commercial pharmaceutical companies and helping to evaluate the effectiveness of BEAM's staff within the industry context.
Sales per employee for the market as a whole
Beam Therapeutics is a biotechnology company working on advanced genetic engineering (base editing). It is in the clinical stage and has no commercial revenue from its products. This metric is irrelevant here. Its value lies in the intellectual potential of its team of scientists striving to create therapies of the future.
Short shares by company, segment and market as a whole
Shares shorted by company Beam Therapeutics Inc. (BEAM)
Beam Therapeutics is a pioneer in base editing, a more precise method of altering DNA than CRISPR. This technology has enormous potential, but it is still in its early stages. This chart reflects the high level of skepticism: investors are betting against the company, fearing failure in expensive clinical trials or safety concerns.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Beam-Therapeutics-Inc.-BEAM&v=1772513723076 "Short Shares Chart for the Company Beam Therapeutics Inc. (BEAM)")
Shares shorted by market segment - Dna
Beam Therapeutics Inc. is a biotech company at the forefront of gene editing. They use "base editing" technology to create drugs for genetic diseases. This chart reflects the total short position in the gene therapy sector. High values indicate general investor skepticism about the safety, efficacy, or commercialization of these breakthrough technologies.
Shares shorted by the overall market
Beam Therapeutics (BEAM) is a pioneer in base editing (gene therapy). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives BEAM of capital for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Beam Therapeutics Inc. (BEAM)
Beam Therapeutics (BEAM) is a biotech company developing base editing technology—a highly precise method for altering DNA to treat genetic diseases. The stock is extremely sensitive to R&D news. This chart shows the extremes of hype: "overbought" (above 70) on breakthrough data or "oversold" (below 30) amid regulatory delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Beam-Therapeutics-Inc.-BEAM&v=1772513723426 "RSI 14 indicator chart for the company's stock Beam Therapeutics Inc. (BEAM)")
RSI 14 Market Segment - Dna
Beam Therapeutics (BEAM) is a biotech company developing "base editing," a next-generation gene-editing technology more precise than CRISPR. This chart tracks the collective sentiment in the DNA/Genomic Technologies sector. It shows when the entire industry is overheated by hype around breakthroughs or oversold by setbacks, providing context for BEAM's valuation.
RSI 14 for the overall market
Beam Therapeutics (BEAM), a company engaged in "genome editing." This graph is its lifeline. Its business is pure R&D. In times of euphoria, investors are willing to fund the "future of medicine." In moments of panic, they flee unprofitable biotech companies, and BEAM risks running out of funds for its breakthrough but expensive research.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BEAM (Beam Therapeutics Inc.)
Beam Therapeutics is a biotech company using advanced base editing technology to create highly precise gene therapies. This chart reflects the collective expert consensus on BEAM's 12-month fair share price, which depends almost entirely on the success of its scientific platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BEAM-Beam-Therapeutics-Inc.&v=1772513723591 "A chart showing analyst consensus forecasts for the expected stock price. BEAM (Beam Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price BEAM (Beam Therapeutics Inc.)
Beam Therapeutics (BEAM) is a pioneer in base editing, a more precise gene editing method (CRISPR 2.0) for treating genetic diseases. This chart is an R&D barometer. It measures the gap between the price and the consensus target, reflecting the enormous potential analysts see in their breakthrough scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BEAM-Beam-Therapeutics-Inc.&v=1772513723639 "A chart showing the difference between the consensus forecast and the actual stock price. BEAM (Beam Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Beam Therapeutics is a biotech company pioneering base editing, a more precise version of CRISPR technology. This chart shows analysts' overall expectations for the DNA technology sector. It reflects whether experts believe in the commercial potential of the next generation of gene therapy.
Analysts' consensus forecast for the overall market share price
Beam Therapeutics (BEAM) is a cutting-edge biotech developing genome editing technology. It's a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs with revolutionary potential. Pessimism = risk aversion, and capital for R&D dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Beam Therapeutics Inc.
Beam Therapeutics is a pioneer in base editing, considered the next, more precise generation of genetic engineering after CRISPR. This is a pure R&D bet on breakthrough science. This graph is an assessment of their platform. Its dynamics depend entirely on news from the lab and the progress of their preclinical and clinical trials.
AKIMA Market Segment Index - Dna
Beam Therapeutics is a pioneer in next-generation gene therapy; the company develops base editing technology—an ultra-precise method for editing a single DNA letter (instead of cutting with CRISPR). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Beam's revolutionary base editing R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Beam Therapeutics is a leader in DNA base editing. This next generation of CRISPR technology promises more precise treatments for genetic diseases. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding such cutting-edge biotech companies.
